Dexcom's landmark CONNECT trial, now published in the NEJM, could drive a pivotal CMS coverage decision for type 2 diabetes patients this year.

DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its ...

DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The ...

The CONNECT trial found greater A1C reductions and more time in target glucose range among adults using continuous glucose monitoring.

A list of domestic and international medical and healthcare news for the past week, along with brief commentary. On October ...

Medical device company DexCom (NASDAQ:DXCM) reported in Q3 2026, with sales up 11.2% year on year to $1.34 billion. The ...

Full-year revenue guidance moved from "$5.18 billion to $5.25 billion" in Q2 (Executive VP Sylvain, Q2) to "$5.20 billion to $5.25 billion" in Q3 (Executive VP Sylvain, Q3); Q3 also announced ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...

The new 2026 data highlights an urgent opportunity for people with Type 2 diabetes: closing the gap between CGM's proven, ...